STOP TB Partnership
Download
Report
Transcript STOP TB Partnership
The Lilly MDR-TB Partnership
Local Action, Global Impact
World Bank Donor Forum
Paris, France
20 May 2008
Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Facts & Figures
TB kills close to two million people every year
TB kills one person every 20 seconds
4600 people will die of TB by the end of today -- most of whom are in
their most productive working years (ages 15 to 54)
2 billion people are infected with TB worldwide -- 1 in 10 will become sick
with active TB
12 million people worldwide with HIV/AIDS-TB co-infection
One-third of AIDS patients die of TB, making TB the leading cause of
death among AIDS patients
Nearly 500,000 of the 9.2 million new cases of TB every year are
multidrug-resistant
China and India account for half the world’s MDR-TB cases
Highest MDR-TB incidences are in countries of the former Soviet Union
Global MDR-TB Challenge:
Businesses & communities at risk
MDR-TB prolonged and complex
treatment can result in poor patient
compliance and development of drug
resistance
Decline in worker productivity to the
order of US$13 billion annually
Lilly has organized health professionals,
businesses, academic institutions, and
communities in a comprehensive US$135
million MDR-TB program
Since 2003, Lilly has lead a comprehensive approach to
fighting MDR-TB through
Community Support
and Patient
Advocacy
Awareness and
Prevention
Treatment, Training
and Surveillance
Research
Transferring
Technology
Reaching patients
throughout the world
MISSION: to combat the growing MDR-TB
pandemic and to support the Global Plan
to Stop TB.
The Partners
Aspen Pharmacare, South Africa
International Council of Nurses
International Federation of Red Cross &
Red Crescent Societies
International Hospital Federation
Harvard Medical School & Partners in Health
Hisun Pharmaceutical, China
Purdue University, USA
Results Educational Fund
Shasun Chemicals and Drugs, India
SIA International, Russia
Stop TB Partnership
TB Alert and TB Survival Project
U.S. Centers for Disease Control & Prevention
World Economic Forum
World Health Organization
World Medical Association
Reaching patients
throughout the world
Transfer of Technology
Share Lilly’s specific and general
manufacturing knowledge
Create self-sustaining centers of
manufacturing excellence capable
of providing additional products
and employment
Offer manufacturing firms in MDRTB “hot spots” (China, India,
Russia, South Africa) the
technology to produce two second
line TB drugs
Technical training in manufacturing
and Good Business Practices with
the support from Purdue University
Provide Lilly staff on-site for
technical assistance/training
Support reliable generic producers
to ensure expanded multi-source
availability of the two drugs
Transferring Technology
360 degree approach: examples
Healthcare Professional Education Program
International Council of Nurses (ICN)
Scope/reach: more than 13 million nurses worldwide
Sample 1 activity: Training of Trainers
Sample 2 activity: Development of framework and advocacy for TB
and MDR-TB curriculum in nursing schools
World Medical Association (WMA)
Scope/reach: 7 million physicians worldwide
Sample 1 activity: Develop distance learning course for physicians
addressing the clinical aspects of MDR-TB
Sample 2 activity: Conduct in-country training with local medical
associations
International Hospital Federation (IHF)
Scope/reach: 50,000 hospital facilities worldwide
Sample activity: Development of MDR-TB control manuals and
disseminated to 40,000 public and private hospitals and clinics
360 degree approach: examples
Community Support and Patient Advocacy
International Federation of Red Cross and Red Crescent
(IFRC)
Sample activity: Community support to people living with MDR-TB to
ensure better access to care and improved compliance
Awareness and Prevention
TB Survival Project and TB Alert
Sample activity: Patient-led initiative to raise awareness and engage
patients and their families worldwide
STOP TB Partnership
Sample activity: Advocacy and awareness campaign involving football
star Luis Figo as goodwill ambassador
Research and Development
Establishment of a not-for-profit early phase drug to integrate medicinal
chemistry expertise from the pharmaceutical industry with academic
expertise in chemistry, microbiology and TB (basic biology genetics and
molecular biology)
Includes collaboration with the Infectious Disease Research Institute
(Seattle, USA), National Institute of Allergy and Infectious Diseases
(USA), Global Alliance for TB Drug Development, etc.
360 degree approach: examples
TB and MDR-TB in the workplace
Partnership with the World Economic Forum (WEF)
Develop a Global Awareness Toolkit for Tuberculosis/MDR-TB in the Workplace and
disseminate through WEF member companies
Provide educational material targeting employees and in-plant healthcare staff
Pilot-tested by the WEF in India and being adapted for other high-burden countries
with large business communities
Advocacy and awareness in the workplace
Partnership with the Global Business Coalition (GBC)
GBC scope/reach: 220 cross-cutting multinational companies worldwide (e.g., Coca
Cola Company, Citibank, General Motors, Deutsche Post World Net, L’Oréal,
Siemens, etc.)
Distributed 400,000 card decks with TB awareness/advocacy messages in Beijing train
stations (target: migrant workers)
Contact Information
Dr Patrizia Carlevaro
Head, International Aid Unit
Eli Lilly and Company
Geneva, Switzerland
[email protected]
www.lilly.com
www.lillymdr-tb.com